There is a frustrating local and global shortage of three specific ADHD medications. This problem is caused by manufacturing difficulties and the increased global demand. It’s expected that this shortage will continue until late in the year 2024. This shortage is causing serious issues for patients and families who have already experienced a challenging year. Often doctors are advised not to prescribe ADHD medication to new patients and to reserve supplies for those already taking the medications.
The impact of the ADHD medication shortage is widespread. According to ADDitude, 38% of caregivers and adults in the United States had trouble getting their prescription medications in the past year. Some patients are being sent back to specialist services for a change in medication, adding to already long waiting lists and causing even more delays.
This shortage also leads to interruption in treatment for ADHD patients, potentially worsening their symptoms and affecting various aspects of their lives. In some places, the shortage may increase medication prices, adding to the already high healthcare costs.
It is crucial to improve access to ADHD care. Redirecting patients to specialists along with the shift from digital to handwritten prescriptions worsens the problem. Urgent initiatives, such as allowing digital prescription and along with support from pharmacists and for alternative medications are necessary.
The scarcity of ADHD medication reflects broader issues. Regulatory reforms could address shortages, manufacturing challenges, and more to enhance the supply of this crucial treatment. Beyond shortages, challenges persist, including the DEA’s rollback of telehealth rules introduced during the pandemic. Although the temporary extension until December 2024 is a positive step, it doesn’t guarantee a permanent solution for those with ADHD.